Radiopharmaceutical therapy in cancer: clinical advances and challenges

Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.

Abstract

Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate by physiological mechanisms. Almost all radionuclides used in RPT emit photons that can be imaged, enabling non-invasive visualization of the biodistribution of the therapeutic agent. Compared with almost all other systemic cancer treatment options, RPT has shown efficacy with minimal toxicity. With the recent FDA approval of several RPT agents, the remarkable potential of this treatment is now being recognized. This Review covers the fundamental properties, clinical development and associated challenges of RPT.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Approval / methods
  • Humans
  • Neoplasms / drug therapy*
  • Radiopharmaceuticals / pharmacology*
  • Radiopharmaceuticals / therapeutic use*
  • Tissue Distribution / physiology
  • United States
  • United States Food and Drug Administration

Substances

  • Radiopharmaceuticals